by Virtus | Jan 6, 2026 | Respiratory Preclinical Research
Preclinical efficacy testing respiratory programmes rely on carefully selected experimental models to determine whether a candidate therapy produces measurable biological benefit before advancing into clinical studies. In respiratory drug development, early evidence...
by Virtus | Jan 6, 2026 | Respiratory Preclinical Research
Translational respiratory models are a fundamental component of early stage respiratory drug development, enabling sponsors to bridge findings from preclinical respiratory studies with human disease biology. These models are widely used to evaluate mechanism of...
by Virtus | Dec 22, 2025 | COPD & Chronic Airway Disease Models
Cigarette smoke models are widely used in preclinical COPD research to investigate disease mechanisms, evaluate therapeutic efficacy, and support respiratory drug development. Chronic exposure to cigarette smoke is a primary risk factor for COPD and drives many of the...
by Virtus | Dec 22, 2025 | Viral & Rhinovirus Models
Rhinovirus infection models are widely used in preclinical antiviral research to investigate respiratory viral pathogenesis, evaluate therapeutic efficacy, and support early-stage respiratory drug development. Rhinoviruses are a common cause of respiratory infections...
by Virtus | Dec 22, 2025 | Respiratory Preclinical Research
COPD preclinical models are widely used in respiratory drug development to evaluate disease-relevant mechanisms, assess translational potential, and generate early efficacy data before clinical studies. As a chronic airway disease with complex inflammatory,...
